Mode
Text Size
Log in / Sign up
N/A N=20 Treatment

High Intensity Non-Invasive Positive Pressure Ventilation (HINPPV)

Chronic Obstructive Pulmonary Disease (COPD)

Enrolled (actual)
20
Serious AEs
44.4%
Results posted
Jan 2019
Primary outcome: Primary: Daytime Partial Pressure of Carbon Dioxide in Arterial Blood (PaCO2) — 53; 50 mmHg — p=0.01

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Bilevel positive airway pressure (BiPAP) (Device)
Age
Pediatric, Adult, Older Adult
Sex
All
Sponsor
Philips Respironics
Primary completion
Dec 2012

Outcome Measures

OutcomeResultp-value
PRIMARY
Daytime Partial Pressure of Carbon Dioxide in Arterial Blood (PaCO2)
53; 50 0.01 sig
SECONDARY
Health Status
4.34; 4.78
SECONDARY
Maximal Inspiratory Pressure
7.04; 6.85
SECONDARY
Exercise Capacity
211; 236
SECONDARY
Dyspnea at Rest and With Exertion
0.7; 6.9; 0.6; 4.6
SECONDARY
Sleepiness
9.3; 7.2
SECONDARY
Duration of Sleep
329; 337
SECONDARY
Efficiency of Sleep
80.6; 83.6

Summary

The purpose of this pilot study is to evaluate the effect of high intensity non-invasive positive pressure ventilation (HINPPV) for stable, hypercapnic COPD patients. The investigators believe that HINPPV, used at least 6 hours nocturnally over three months, will benefit the stable hypercapnic COPD patient through a reduction in the daytime partial pressure of carbon dioxide in arterial blood (PaCO2) levels.

Eligibility Criteria

Inclusion Criteria

  • Patient diagnosed with chronic obstructive pulmonary disease (COPD)
  • Age 90% predicted by plethysmography
  • Body Mass Index (BMI) 48 mm Hg) with one of the following symptoms of hypercapnia:
  • Fatigue
  • Sleepiness
  • Headaches
  • Post hospital discharge at least one month prior to screening visit
  • Participant is willing and able to complete all required assessments and procedures
  • Participant has no child bearing potential OR a negative pregnancy test in a woman of childbearing potential

Exclusion Criteria

  • FEV1 15 per hour]
  • Current Non-invasive Positive Pressure Ventilation (NIPPV), Positive Airway Pressure (PAP) or Non-invasive Ventilation (NIV) users
  • Signs / symptoms of acute exacerbation within the previous month: two of the following criteria:
  • Increasing cough
  • Purulent sputum
  • Current use of antibiotics
  • pH 90% on 5L/min ( five liters) nasal O2 at rest
  • Sustained need for >10 mg prednisone daily or equivalent dose of other systemic corticosteroid
  • Pregnancy
  • Excessive alcohol intake (≥ 6oz hard liquor daily), or illicit drug use
  • Daily use of narcotics (greater than 30 mg morphine equivalent)
  • Patient is currently enrolled in another interventional clinical trial
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01214200). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search